Clinical Trials Logo

Filter by:
NCT ID: NCT06442488 Recruiting - Clinical trials for Respiratory Insufficiency

Wearable Wireless Respiratory Monitoring System That Detects and Predicts Opioid Induced Respiratory Depression

Start date: May 1, 2024
Phase:
Study type: Observational

An observational study will be conducted in approximately 14 participants to evaluate the ability of a wearable, wireless acoustic Respiratory Monitoring System (RMS) to accurately measure a participant's respiratory rate, tidal volume, minute ventilation, and duration of apnea in a noisy environment. Sensor accuracy will be measured with adaptive filtering and active noise cancellation turned on versus turned off.

NCT ID: NCT06442358 Recruiting - Perinatal Care Clinical Trials

Self Biophysical Profile Using a Home Ultrasound Device Proof of Concept

Start date: April 10, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to assess if patients presenting for antenatal testing can complete a Bio Physical Score (BPP) with a home-use ultrasound with remote clinician guidance.

NCT ID: NCT06442098 Recruiting - Clinical trials for Reading Disorder, Developmental

Camp SMART Speech to Print Summer Literacy Camp

Start date: June 11, 2024
Phase: N/A
Study type: Interventional

This project aims to explore the feasibility and efficacy of a 6-week, intensive summer literacy intervention provided to children in 1st-3rd grades.

NCT ID: NCT06441890 Recruiting - Breast Cancer Clinical Trials

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

BRE-10
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care

NCT ID: NCT06441695 Recruiting - Cognitive Change Clinical Trials

Acute Effects of PLT Health Solutions zümXR Extended-Release Caffeine

Start date: June 3, 2024
Phase: N/A
Study type: Interventional

This will be a (2 visit) double-blind, randomized, crossover design clinical study to assess the potential benefits of ER-CAFF versus IR-CAFF by assessing its impact on side effect profiles, mood states, alertness, and cognitive abilities following ingestion after a suboptimal night of sleep. This study will enroll 30 healthy men and women who will be recruited by word of mouth, email contact, and direct contact from the greater Tampa Bay Area. To account for potential dropouts, we aim to enroll approximately 20% over the desired sample size (total of 36 participants). The anticipated study period will last approximately 2 weeks. After initial pre-screening, participants will report to the laboratory on two separate occasions after an overnight fast (10 hours minimum). Participants will be required to have a night of partial sleep deprivation the night before (<5 hours sleep), which will be confirmed by self reported sleep logs and objective multisensor (triaxial accelerometry and cardiac data) wearable devices to accurately measure sleep deficit data. Upon arrival, participants will undergo baseline (BL) testing and then ingest a bolus of one study product with 4-8 ounces of water: 400 mg zümXR extended-release caffeine (ER-CAFF), or 400 mg of immediate-release caffeine anhydrous (IR-CAFF) (2 group, crossover design). Thereafter, participants will undergo subsequent testing sessions at 45, 60, 90, 135, 240, 300, 360, and 420 minutes post-supplementation. After the 4-hour (240 min) measurements, a caffeine-free food bar will be provided. This same food bar will also be offered to participants following the final 7-hour (420 min) measurements. The precise measures and timepoints for the measures are further defined below. There will be a one-week minimum washout period between treatments in the crossover design.

NCT ID: NCT06441318 Recruiting - Clinical trials for Healthy Participants

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

Start date: July 12, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of povorcitinib on the QT/QTc Interval in healthy participants.

NCT ID: NCT06440850 Recruiting - Clinical trials for Thyroid Gland Papillary Carcinoma

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Start date: November 30, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy. Vemurafenib and cobimetinib are used in patients whose cancer has a mutated (changed) form of a gene called BRAF. They are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving vemurafenib and cobimetinib may work better to treat patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.

NCT ID: NCT06440577 Recruiting - Decision Making Clinical Trials

Craving & Decision-Making

Start date: June 2024
Phase: N/A
Study type: Interventional

Craving is the strong desire for something, such as for substances in drug addiction and food or other activities in everyday life. Recent work suggests craving can influence how people make decisions and assign value to choice options available to them, yet the neural mechanisms underlying these interactions between craving and valuation remain unknown. To address this, this study uses cognitive decision-making tasks that measure how much individuals will pay (from a study endowment) to have everyday consumer items or snack foods when they crave something specific (opioids or a specific snack, respectively). First, the study will identify the neural mechanisms for how drug craving (craving for opioids) interacts with valuation for consumer items that have associations with drug use or not in people receiving treatment for opioid use disorder (OUD). This will be evaluated in the activity patterns and interactions among brain regions involved in craving and value assignment during decision-making. Then, the study will examine for parallel mechanisms for how food craving (craving for a specific snack) interacts with valuation for snack food items that have similar features to the craved snack or not in people receiving treatment for OUD and non-psychiatric community control participants.

NCT ID: NCT06440538 Recruiting - Clinical trials for Cervical Spinal Cord Injury

Rebuilding Inter-limb Transfer in Cervical SCI

Start date: February 15, 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study in people living with cervical Spinal Cord Injury (SCI) is to examine the effects of paired neurostimulation (i.e., PCMS) combined with contralateral motor training on inter-limb transfer of ballistic motor and hand dexterity skills.

NCT ID: NCT06440473 Recruiting - Healthy Skin Clinical Trials

Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin

Start date: May 28, 2024
Phase: Phase 4
Study type: Interventional

The goal of this study is to visualize the deposition of topical 0.3% roflumilast (Zoryve) compared to vehicle using Line-Field Optical Coherence Tomography (LC-OCT) in vivo in healthy skin. We hypothesize that the application of topical 0.3% roflumilast (Zoryve) will result in distinct patterns of deposition within the epidermal and dermal layers compared to the vehicle. Specifically, we anticipate observing deeper penetration and more uniform distribution of roflumilast within the skin layers, indicative of enhanced efficacy, as visualized by LC-OCT imaging.